10x Genomics, Inc. TXG
TXG Rating
TXG Rating Factors
TXG Company Overview
10x Genomics, Inc. is a U.S.-based life sciences technology company focused on developing tools and platforms for analyzing biological systems at high resolution. The company operates primarily within the genomics, biotechnology, molecular diagnostics, and life sciences research industries. Its technologies are widely used in single-cell analysis, spatial biology, and immune profiling, supporting applications in academic research, pharmaceutical development, translational medicine, and clinical discovery. Revenue is generated primarily through sales of instruments, consumables, and software services tied to recurring research workflows.
The company’s core business is centered on integrated genomic analysis platforms, including the Chromium, Visium, and Xenium product families. These systems enable researchers to examine gene expression, chromatin accessibility, and cellular interactions with single-cell and spatial resolution. 10x Genomics has built a competitive position through proprietary microfluidics technology, high-throughput sequencing compatibility, and an ecosystem of consumables that generate recurring revenue. Founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness, the company expanded rapidly following the commercialization of its Chromium platform and became publicly traded on Nasdaq in 2019.
TXG Income Statement
TXG Balance Sheet
TXG Price History
TXG Valuation
TXG Dividends and Shares
TXG Corporate Info
Pleasanton, CA 94588-3260